CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

Core Insights - CytoDyn Inc. has successfully closed a financing round, raising $17.5 million in gross proceeds, with Paulson Investment Company as the placement agent [1][3] - The financing reflects strong investor confidence in CytoDyn's clinical progress and development strategy for leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor [2][3] Financial Impact - The net proceeds from the financing will primarily support the advancement of CytoDyn's clinical development programs, including ongoing and planned trials, regulatory engagement, and data analysis [3] - The financing is expected to fund current operations into 2027, strengthening the company's balance sheet and supporting its strategic priorities [3] Company Overview - CytoDyn is a clinical-stage oncology company focused on advancing leronlimab, which has therapeutic potential across multiple indications, including triple-negative breast cancer and metastatic colorectal cancer [1][5] - The company is dedicated to improving patients' quality of life through therapeutic innovation and is committed to integrity, responsibility, and service [5]